Indoco Remedies Reports Q2 FY26 Results: Revenue Up, Consolidated Net Loss, Subsidiary Going Concern Noted
Indoco Remedies reported Q2 FY26 standalone revenue up 8.8% and profit up. Consolidated revenue increased, but a net loss was posted. Auditors noted going concern uncertainty for two subsidiaries.
The impact is medium as the announcement contains both positive elements (revenue growth, standalone profit) and significant concerns (consolidated loss, auditor's emphasis on subsidiary going concern). This mixed bag of information is likely to result in a moderate market reaction rather than a strong positive or negative shift, as investors will weigh the growth against the underlying financial health issues of subsidiaries.
The sentiment is neutral due to mixed financial results: standalone profits increased and overall revenues grew, but consolidated results show a net loss (though slightly reduced for the quarter, it significantly worsened for the half-year). The auditor's 'Emphasis of Matter' regarding the going concern of two subsidiaries due to substantial losses and negative net worth is a significant negative factor, offsetting the positive revenue growth and management's optimistic outlook.
Indoco Remedies Limited's Board of Directors met on November 6, 2025, to approve the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 30, 2025. The Statutory Auditors, M/s. Gokhale & Sathe, issued an Unmodified Limited Review Report on these results.
* Standalone Financial Highlights (Q2 FY26 vs Q2 FY25): * Revenue from Operations grew by 8.8% to ₹429.30 crore, compared to ₹394.58 crore in the prior year. * Profit for the period increased to ₹15.05 crore from ₹12.79 crore. * Basic Earnings Per Share (EPS) stood at ₹1.63, up from ₹1.39.
* Consolidated Financial Highlights (Q2 FY26 vs Q2 FY25): * Revenue from Operations increased by 9.56% to ₹471.83 crore, compared to ₹430.66 crore in the previous year. * The company reported a consolidated net loss of ₹9.21 crore, a slight improvement from a loss of ₹10.01 crore in the same quarter last year. * For the Half Year Ended September 30, 2025, the consolidated net loss significantly widened to ₹45.55 crore, compared to a loss of ₹8.20 crore in the prior half-year. * Consolidated Basic EPS was ₹(1.00) compared to ₹(1.09).
* Management Commentary: * Ms. Aditi Panandikar, Managing Director, stated that international formulation and API businesses experienced good growth this quarter. * The India formulation business performance was impacted by a revision in GST rates. * She expressed confidence in regaining momentum in the coming quarters.
* Auditor's Emphasis of Matter: * The auditors highlighted significant losses and negative net worth in two subsidiaries: * FPP Holding LLC: Incurred a net loss of ₹8.54 crore for the quarter and a cumulative net loss of ₹12.27 crore for the half-year. It has a negative net worth of ₹35.11 crore. * Warren Remedies Private Limited: Incurred a net loss of ₹14.35 crore for the quarter and a cumulative loss of ₹19.91 crore for the half-year. It has a negative net worth of ₹50.87 crore. * These conditions indicate a material uncertainty regarding the ability of these subsidiaries to continue as going concerns. However, management's impairment assessment concluded that recoverable amounts exceeded carrying values, and thus, no impairment provision was deemed necessary.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.